PE20030742A1 - Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada - Google Patents
Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejoradaInfo
- Publication number
- PE20030742A1 PE20030742A1 PE2003000013A PE2003000013A PE20030742A1 PE 20030742 A1 PE20030742 A1 PE 20030742A1 PE 2003000013 A PE2003000013 A PE 2003000013A PE 2003000013 A PE2003000013 A PE 2003000013A PE 20030742 A1 PE20030742 A1 PE 20030742A1
- Authority
- PE
- Peru
- Prior art keywords
- orally active
- pharmaceutical compositions
- improved bioavailability
- taxan
- taxan derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DE 1% A 20% DE UN DERIVADO DE TAXANO ORALMENTE ACTIVO DE FORMULA I, II; DONDE R ES FENILO, ISOPROPILO, TER BUTILO; R1 ES CORZ; Rz ES (CH3)3CCH2, CH3(CH2)3O-, CICLOBUTILO, CICLOHEXILOXI, 2-FURILO; R2 ES CH3COO; DE 10% A 99% DE UN AGENTE DE SOLUBILIZACION TAL COMO POLIETILENGLICOL, GLICERIDO POLIGLICOLIZADO, SURFACTANTE ANFIFILICO, DERIVADO DE ESTER DE ACIDO GRASO DE UN ALCOHOL POLIHIDRICO, ACEITE VEGETAL, MINERAL Y ACIDO CITRICO. LA COMPOSICION PROPORCIONA UNA ABSORCION ORAL EFECTIVA Y CONSISTENTE DEL PRINCIPIO ACTIVO Y PUEDE SER UTIL PARA INHIBIR EL DESARROLLO TUMORAL Y PARA EL TRATAMIENTO DE CANCER DE OVARIO, MAMA, CEREBRO, PROSTATA, COLON, ESTOMAGO, RINON
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34288901P | 2001-12-20 | 2001-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030742A1 true PE20030742A1 (es) | 2003-09-02 |
Family
ID=23343716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003000013A PE20030742A1 (es) | 2001-12-20 | 2003-01-06 | Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada |
Country Status (24)
Country | Link |
---|---|
US (1) | US20030220391A1 (es) |
EP (1) | EP1465618A2 (es) |
JP (1) | JP2006501134A (es) |
KR (1) | KR20040066921A (es) |
CN (1) | CN1273130C (es) |
AR (1) | AR037951A1 (es) |
AU (1) | AU2002361701A1 (es) |
BR (1) | BR0215184A (es) |
CA (1) | CA2470826A1 (es) |
GE (1) | GEP20063806B (es) |
HR (1) | HRP20040545A2 (es) |
HU (1) | HUP0500843A2 (es) |
IL (1) | IL162118A0 (es) |
IS (1) | IS7306A (es) |
MX (1) | MXPA04005877A (es) |
NO (1) | NO20043101L (es) |
PE (1) | PE20030742A1 (es) |
PL (1) | PL374283A1 (es) |
RS (1) | RS52904A (es) |
RU (1) | RU2004119557A (es) |
TW (1) | TW200302086A (es) |
UY (1) | UY27598A1 (es) |
WO (1) | WO2003053350A2 (es) |
ZA (1) | ZA200404584B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0307913A (pt) * | 2002-02-25 | 2005-01-11 | Lyfjathroun Hf | Uso de uma composição, composição farmacêutica para administração nasal, e, métodos para eliciar um efeito terapêutico, profilático e/ou diagnóstico em um mamìfero, para obter um inìcio rápido de um efeito terapêutico, profilático e/ou diagnóstico de uma substância ativa em um mamìfero e para melhorar a biodisponibilidade de um efeito terapêutico, profilático e/ou diagnóstico de uma substância ativa em um mamìfero |
US6855332B2 (en) * | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
KR100533458B1 (ko) | 2002-07-20 | 2005-12-07 | 대화제약 주식회사 | 파클리탁셀의 가용화용 조성물 및 그의 제조 방법 |
EP1498120A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid formulations for the oral administration of taxoids |
PL1664033T3 (pl) | 2003-09-25 | 2008-04-30 | Tapestry Pharmaceuticals Inc | Analogi 9,10-alfa, alfa-OH-taksanu i sposoby ich wytwarzania |
US20060088591A1 (en) * | 2004-10-22 | 2006-04-27 | Jinghua Yuan | Tablets from a poorly compressible substance |
US20060116420A1 (en) * | 2004-11-23 | 2006-06-01 | Ramakrishnan Chidambaram | Crystalline forms of 3'-tert-Butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel |
AU2012202903B2 (en) * | 2005-02-18 | 2014-12-11 | Abraxis Bioscience, Inc. | Drugs with improved hydrophobicity for incorporation in medical devices |
CN105879114A (zh) * | 2005-02-18 | 2016-08-24 | 阿布拉西斯生物科学公司 | 用于整合入医疗装置的疏水性改善的药物 |
EP1907009A4 (en) * | 2005-07-15 | 2009-09-02 | Angiochem Inc | USE OF APROTININ POLYPEPTIDES AS CARRIER IN PHARMACEUTICAL CONJUGATES |
US20070015834A1 (en) * | 2005-07-18 | 2007-01-18 | Moshe Flashner-Barak | Formulations of fenofibrate containing PEG/Poloxamer |
BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
WO2007134354A1 (de) * | 2006-05-23 | 2007-11-29 | Ebewe Pharma Ges.M.B.H. Nfg. Kg | Pharmazeutische formulierung |
US11786504B2 (en) | 2006-09-28 | 2023-10-17 | Tapestry Pharmaceuticals, Inc. | Taxane analogs for the treatment of brain cancer |
US11873308B2 (en) | 2006-11-06 | 2024-01-16 | Tapestry Pharmaceuticals, Inc. | Biologically active taxane analogs and methods of treatment by oral administration |
WO2008121476A1 (en) | 2007-03-28 | 2008-10-09 | Tapestry Pharmaceuticals, Inc. | Biologically active taxane analogs and methods of treatment by oral administration |
EP1946747A1 (en) * | 2007-01-17 | 2008-07-23 | Sandoz AG | Pharmaceutical composition of improved stability containing taxane derivatives |
WO2008109360A1 (en) | 2007-02-28 | 2008-09-12 | Tapestry Pharmaceuticals, Inc | Taxane analogs for the treatment of brain cancer |
US9089544B2 (en) * | 2007-08-24 | 2015-07-28 | Slotervaart Participaties Bv | Composition |
MX2010002179A (es) * | 2007-08-24 | 2010-04-27 | Stichting Het Nl Kanker I | Composicion para el tratamiento de enfermedades neoplasicas. |
EP2222273A2 (en) * | 2007-11-12 | 2010-09-01 | Novartis AG | Liquid compositions comprising valsartan |
EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
ES2344674B1 (es) | 2008-08-07 | 2011-06-29 | Gp Pharm, S.A. | Composicion farmaceutica inyectable de taxanos. |
CN102245642A (zh) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | Glp-1激动剂的结合物及其用途 |
JP5670421B2 (ja) | 2009-03-31 | 2015-02-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | コンポーネント表面のコーティング方法 |
EP2432531B1 (de) | 2009-05-18 | 2019-03-06 | Boehringer Ingelheim International GmbH | Adapter, inhalationseinrichtung und zerstäuber |
CN102038635A (zh) | 2009-10-23 | 2011-05-04 | 天津天士力集团有限公司 | 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法 |
JP5715640B2 (ja) | 2009-11-25 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
EP2504051B1 (en) | 2009-11-25 | 2019-09-04 | Boehringer Ingelheim International GmbH | Nebulizer |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
EP2694220B1 (de) | 2011-04-01 | 2020-05-06 | Boehringer Ingelheim International GmbH | Medizinisches gerät mit behälter |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
WO2013152894A1 (de) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Zerstäuber mit kodiermitteln |
EP2777691A1 (en) * | 2013-03-14 | 2014-09-17 | Pharmachemie B.V. | Taxoid - Purification of Liquid Excipients |
EP3030298B1 (en) | 2013-08-09 | 2017-10-11 | Boehringer Ingelheim International GmbH | Nebulizer |
ES2836977T3 (es) | 2013-08-09 | 2021-06-28 | Boehringer Ingelheim Int | Nebulizador |
CN106232166B (zh) | 2014-05-07 | 2020-04-14 | 勃林格殷格翰国际有限公司 | 喷雾器 |
PL3139984T3 (pl) | 2014-05-07 | 2021-11-08 | Boehringer Ingelheim International Gmbh | Nebulizator |
CN106255554B (zh) | 2014-05-07 | 2021-05-04 | 勃林格殷格翰国际有限公司 | 容器、喷雾器及用途 |
CN103980232A (zh) * | 2014-06-05 | 2014-08-13 | 北京诺普德医药科技有限公司 | 10-乙酰基多西紫杉醇及其用途 |
DK3307326T3 (da) | 2015-06-15 | 2020-10-19 | Angiochem Inc | Fremgangsmåder til behandling af leptomeningeal karcinomatose |
TWI752750B (zh) | 2015-09-30 | 2022-01-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
CN108066335B (zh) * | 2016-11-11 | 2020-02-21 | 北京康辰药业股份有限公司 | 一种含有紫杉醇或其类似物的药物组合物及其制备方法 |
FR3113238B1 (fr) | 2020-08-05 | 2024-04-05 | Gattefosse Sas | Utilisation comme excipient, d’un melange de macrogolglyceride laurique et de polyethylene glycol |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601675B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
US5817321A (en) * | 1992-10-08 | 1998-10-06 | Supratek Pharma, Inc. | Biological agent compositions |
DK0674510T3 (da) * | 1992-11-27 | 1999-05-10 | Napro Biotherapeutics Inc | Injicerbart præparat omfattende paclitaxel |
US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
US6395770B1 (en) * | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
CA2250295C (en) * | 1996-03-12 | 2008-12-30 | Pg-Txl Company L.P. | Water soluble paclitaxel prodrugs |
US5756537A (en) * | 1996-11-08 | 1998-05-26 | Parkash S. Gill, M.D., Inc. | Regime for paclitaxel in Kaposi's sarcoma patients |
US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US6515016B2 (en) * | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US5980936A (en) * | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
HUP0101457A3 (en) * | 1997-12-31 | 2003-01-28 | Bristol Myers Squibb Co | Antitumor 2-aroyl-4-acyl paclitaxel analogs and medicaments containing them , their intermediates and method for producing them |
IL131217A0 (en) * | 1998-03-10 | 2001-01-28 | Napro Biotherapeutics Inc | Novel methods and compositions for delivery of taxanes |
US6979456B1 (en) * | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
PT1178979E (pt) * | 1999-05-17 | 2004-04-30 | Bristol Myers Squibb Co | Novas condicoes de reaccao para a clivagem de eteres de sililo na preparacao de paclitaxel (taxol(r)) e analogos de paclitaxel |
DE60010476T2 (de) * | 1999-08-11 | 2005-04-14 | Bristol-Myers Squibb Co. | Verfahren zur Herstellung eines C-4-Methylcarbonat-Analogons von Paclitaxel |
US6136846A (en) * | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
US6916942B2 (en) * | 2000-02-03 | 2005-07-12 | Bristol-Myers Squibb Company | Process for the preparation of C-4 carbonate taxanes |
US6750246B1 (en) * | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
US6919370B2 (en) * | 2000-11-28 | 2005-07-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
TWI297335B (en) * | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
US20040092428A1 (en) * | 2001-11-27 | 2004-05-13 | Hongming Chen | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof |
-
2002
- 2002-12-12 BR BRPI0215184-7A patent/BR0215184A/pt not_active IP Right Cessation
- 2002-12-12 IL IL16211802A patent/IL162118A0/xx unknown
- 2002-12-12 AU AU2002361701A patent/AU2002361701A1/en not_active Abandoned
- 2002-12-12 PL PL02374283A patent/PL374283A1/xx not_active Application Discontinuation
- 2002-12-12 KR KR10-2004-7009593A patent/KR20040066921A/ko not_active Application Discontinuation
- 2002-12-12 RU RU2004119557/15A patent/RU2004119557A/ru not_active Application Discontinuation
- 2002-12-12 GE GE5614A patent/GEP20063806B/en unknown
- 2002-12-12 JP JP2003554110A patent/JP2006501134A/ja not_active Withdrawn
- 2002-12-12 CA CA002470826A patent/CA2470826A1/en not_active Abandoned
- 2002-12-12 HU HU0500843A patent/HUP0500843A2/hu unknown
- 2002-12-12 RS YU52904A patent/RS52904A/sr unknown
- 2002-12-12 WO PCT/US2002/040127 patent/WO2003053350A2/en active Application Filing
- 2002-12-12 CN CNB028254708A patent/CN1273130C/zh not_active Expired - Fee Related
- 2002-12-12 EP EP02797339A patent/EP1465618A2/en not_active Withdrawn
- 2002-12-16 TW TW091136275A patent/TW200302086A/zh unknown
- 2002-12-19 US US10/323,551 patent/US20030220391A1/en not_active Abandoned
- 2002-12-19 AR ARP020105039A patent/AR037951A1/es unknown
- 2002-12-20 UY UY27598A patent/UY27598A1/es not_active Application Discontinuation
-
2003
- 2003-01-06 PE PE2003000013A patent/PE20030742A1/es not_active Application Discontinuation
-
2004
- 2004-06-09 ZA ZA200404584A patent/ZA200404584B/en unknown
- 2004-06-10 IS IS7306A patent/IS7306A/is unknown
- 2004-06-15 HR HR20040545A patent/HRP20040545A2/xx not_active Application Discontinuation
- 2004-06-16 MX MXPA04005877A patent/MXPA04005877A/es unknown
- 2004-07-19 NO NO20043101A patent/NO20043101L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1606437A (zh) | 2005-04-13 |
US20030220391A1 (en) | 2003-11-27 |
ZA200404584B (en) | 2005-09-13 |
JP2006501134A (ja) | 2006-01-12 |
CA2470826A1 (en) | 2003-07-03 |
UY27598A1 (es) | 2003-07-31 |
WO2003053350A2 (en) | 2003-07-03 |
RU2004119557A (ru) | 2005-04-20 |
WO2003053350A3 (en) | 2004-01-15 |
EP1465618A2 (en) | 2004-10-13 |
HRP20040545A2 (en) | 2005-08-31 |
AU2002361701A1 (en) | 2003-07-09 |
CN1273130C (zh) | 2006-09-06 |
HUP0500843A2 (hu) | 2005-12-28 |
MXPA04005877A (es) | 2004-09-13 |
IL162118A0 (en) | 2005-11-20 |
BR0215184A (pt) | 2006-06-06 |
PL374283A1 (en) | 2005-10-03 |
GEP20063806B (en) | 2006-04-25 |
RS52904A (en) | 2006-12-15 |
TW200302086A (en) | 2003-08-01 |
IS7306A (is) | 2004-06-10 |
NO20043101L (no) | 2004-07-19 |
AR037951A1 (es) | 2004-12-22 |
KR20040066921A (ko) | 2004-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030742A1 (es) | Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada | |
DE602005014765D1 (de) | Verfahren dafür | |
CY1105318T1 (el) | Φαρμακευτικες συνθεσεις για απο του στοματος και τοπικη χορηγηση | |
AR067824A1 (es) | Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer. | |
WO2002067864A3 (en) | Coenzyme q products exhibiting high dissolution qualities | |
ATE478129T1 (de) | Kerzenwachs auf triacylglycerin-basis | |
PH12015500930A1 (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
PE20130216A1 (es) | Formulacion topica para un inhibidor de jak | |
DE60218443D1 (de) | Jasmonate enthaltende therapeutische zusammensetzungen für die behandlung von krebs | |
CY1111808T1 (el) | Συνθεσεις εχουσες αποτελεσματα προληψης ή βελτιωσης καταστασεων ή νοσων που προκαλουνται απο εγκεφαλικη υπολειτουργια | |
AR036100A1 (es) | Derivados de naftil benzofurano sustituidos, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos que son inhibidores del inhibidor-1 activador de plasminogeno (pai-1) | |
AR025091A1 (es) | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas. | |
MX340701B (es) | Alquil lactil - lactatos y procesos para fabricar los mismos. | |
MA29775B1 (fr) | Derives de pyrazolone | |
MX354647B (es) | Composicion farmaceutica anticonvulsiva transnasal que comprende un anticonvulsivante escasamente soluble. | |
PE20120788A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos | |
MX2009009997A (es) | Preparacion de la capsula de tamibarotene. | |
RU2010103038A (ru) | Композиции для персонального ухода, обладающие ослабленным раздражающим действием на глаза | |
AR076263A1 (es) | Composiciones y metodos para tratar cancer. uso. | |
PE20020833A1 (es) | Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponisibilidad oral | |
BR112015013689A2 (pt) | composições fluidas de cuidado oral contendo peróxido | |
AR072333A1 (es) | Composiciones inyectables a base de taxoides | |
JP4884228B2 (ja) | タキソイド−脂肪酸コンジュゲート及びその医薬組成物 | |
JP2608777B2 (ja) | 美白化粧料 | |
EA200802171A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ 2-[4-(4-ФТОР-2-МЕТИЛ-1H-ИНДОЛ-5-ИЛОКСИ)-5-МЕТИЛПИРРОЛО[2,1-f][1,2,4]ТРИАЗИН-6-ИЛОКСИ]-1-МЕТИЛЭТИЛОВОГО ЭФИРА [(1R),2S]-2-АМИНОПРОПИОНОВОЙ КИСЛОТЫ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |